Post Jobs


Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.

Author: Gardacage Meztilkis
Country: Malaysia
Language: English (Spanish)
Genre: Career
Published (Last): 10 March 2006
Pages: 184
PDF File Size: 1.24 Mb
ePub File Size: 14.64 Mb
ISBN: 568-5-21049-340-4
Downloads: 41365
Price: Free* [*Free Regsitration Required]
Uploader: Kegor

No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from eritropoetina of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. Anaemia in Balkan endemic nephropathy. Consult with your healthcare professional before taking any medication. Faculty of Pharmacy, University of Belgrade, Serbia. Always consult your healthcare provider to ensure the eritgopoyetina displayed on this page applies to your personal circumstances.

Noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver. The presented profiles show greater inter-individual variability in Epo concentration but a faster decrease of Epo level during the elimination phase in non-BEN than in BEN patients.

Eritropoyetina Humana Recombinante

Statistical analysis The results were expressed as mean values with standard deviations. Eritropoyetina Humana Recombinante Eritropoyetina Humana Recombinante may be available in the countries listed below.

Djukanovic Lj, Radovanovic Z. Impact of elevated C-reactive protein levels on erythropoiesis stimulating agent ESA dose and responsiveness in hemodialysis patients. We comply with the HONcode standard for trustworthy health information – verify here. Blood samples were centrifuged for 10 min and plasma stored frozen until analysis.

Eritropoyetina Humana Recombinante –

Available for Android and iOS devices. This means it is still under development and may contain inaccuracies. The aim of this study was to compare the recombiinante of beta-erythropoietin beta-Epo given subcutaneously to BEN patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics. Therefore, not only the distribution by itself, but also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.


Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. Subscribe to receive email notifications whenever new articles are published.

Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. As previous erittopoyetina showed that the kidneys contribute to Epo elimination in a very minor fashion 35 and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence.

Basal plasma Epo concentration in BEN patients ranged between 7. Subscribe to receive email notifications whenever new articles are published. Beta-erythropoietin administration and blood sampling.

Renal Injury from Drugs and Chemicals, third edition. The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test. These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.

Among the remaining 96 patients 40 BEN huana 56 others who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using systematic sampling i. The pharmacokinetic parameters of Epo are presented in Table 3. Subscribe to free Drugs. Ingredient matches for Eritropoyetina Humana Eritopoyetina Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Uhmana in the following countries: Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements.


Eritropoyetina Humana Recombinante Delta

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Res Commun Mol Pathol Pharmacol ; Population pharmacokinetics of erythropoietin in critically ill subjects.

Nephrol Dial Transplant ; Further information Always consult your healthcare provider to ensure the information displayed on this page applies to erittopoyetina personal circumstances.

Pavlovic-Kentera V, Djukanovic Lj. Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among reombinante criteria for diagnosis. Pharmacokinetics For pharmacokinetic analysis the predose plasma level of Epo was eritropojetina from all postdose levels of Epo for each patient.

Balkan endemic nephropathy, Human recombinant erythropoietin, Pharmacokinetics. Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante in the following countries:.

Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was eritropoyetia affect Epo elimination in the ANCOVA model.

European best practice guidelines working group: Clin J Am Soc Nephrol ;1: Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

BEN is a slow progressive chronic kidney disease and patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life. By clicking Subscribe, I agree to the Drugs.